Ignite Creation Date:
2025-12-24 @ 7:34 PM
Ignite Modification Date:
2026-02-24 @ 12:14 AM
Study NCT ID:
NCT02348203
Status:
COMPLETED
Last Update Posted:
2022-06-02
First Post:
2015-01-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014029', 'term': 'Tobacco Use Disorder'}], 'ancestors': [{'id': 'D019966', 'term': 'Substance-Related Disorders'}, {'id': 'D064419', 'term': 'Chemically-Induced Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D001241', 'term': 'Aspirin'}, {'id': 'C063449', 'term': 'zileuton'}], 'ancestors': [{'id': 'D012459', 'term': 'Salicylates'}, {'id': 'D062385', 'term': 'Hydroxybenzoates'}, {'id': 'D010636', 'term': 'Phenols'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'schow@azcc.arizona.edu', 'phone': '520-626-3358', 'title': 'Sherry Chow', 'organization': 'University of Arizona'}, 'certainAgreement': {'restrictionType': 'LTE60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Adverse event data were collected from the time that the first dose of study drug was taken until 2 weeks after participants come off the 12-week agent intervention.', 'eventGroups': [{'id': 'EG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO', 'otherNumAtRisk': 31, 'deathsNumAtRisk': 31, 'otherNumAffected': 25, 'seriousNumAtRisk': 31, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO', 'otherNumAtRisk': 32, 'deathsNumAtRisk': 32, 'otherNumAffected': 17, 'seriousNumAtRisk': 32, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Diarrhea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Weight gain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hyperglycemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Flu like symptoms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Weight loss', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 2}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Upper respiratory infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'OG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.15', 'spread': '2.89', 'groupId': 'OG000'}, {'value': '0.26', 'spread': '2.26', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline to 12 weeks (End-of-intervention)', 'description': 'Change in a nasal smoking-related gene expression signature score derived from prior research was compared between the two study arms. Prior research showed that a higher score was observed in never smokers compared to current smokers. An increased score implicated a more favorable intervention effect. There is no minimum or maximum score.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The number of participants analyzed is different from the numbers provided in the Participant Flow Module because gene expression analysis was restricted to samples that met quality metrics.'}, {'type': 'SECONDARY', 'title': 'Changes in Three Lung Cancer Gene Signatures (an 80-gene Bronchial Signature, a PI3K Pathway Gene Signature and a Nasal Diagnostic Gene Signature) in the Nasal Epithelium of Current Smokers', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'OG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO'}], 'classes': [{'title': 'bronchial smoking signature', 'categories': [{'measurements': [{'value': '-1.0', 'spread': '2.87', 'groupId': 'OG000'}, {'value': '-0.43', 'spread': '3.37', 'groupId': 'OG001'}]}]}, {'title': 'PI3 pathway gene signature', 'categories': [{'measurements': [{'value': '-0.32', 'spread': '1.57', 'groupId': 'OG000'}, {'value': '0.42', 'spread': '1.68', 'groupId': 'OG001'}]}]}, {'title': 'nasal diagnostic gene signature', 'categories': [{'measurements': [{'value': '1.82', 'spread': '8.63', 'groupId': 'OG000'}, {'value': '2.17', 'spread': '11.21', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline to 12 weeks (End of Intervention)', 'description': 'Change in three lung cancer gene signatures (an 80-gene bronchial signature, a PI3K pathway gene signature and a nasal diagnostic gene signature) derived from prior research was compared between the two study arms. A decreased signature score implicated a more favorable intervention effect. There is no minimum or maximum score.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The number of participants analyzed is different from the numbers provided in the Participant Flow Module because gene expression analysis was restricted to samples that met quality metrics.'}, {'type': 'SECONDARY', 'title': 'Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers 10-14 Days Post Intervention', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'OG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.24', 'spread': '3.04', 'groupId': 'OG000'}, {'value': '-1.16', 'spread': '3.55', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline to 14 days post intervention', 'description': 'Change (from baseline to 10-14 days off intervention) in a nasal smoking-related gene expression signature score derived from prior research was compared between the two study arms. Prior research showed that a higher score was observed in never smokers compared to current smokers. An increased score implicated a more favorable intervention effect. There is no minimum or maximum score.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The number of participants analyzed is different from the numbers provided in the Participant Flow Module because gene expression analysis was restricted to samples that met quality metrics.'}, {'type': 'SECONDARY', 'title': 'Changes in Three Lung Cancer Gene Signatures (an 80-gene Bronchial Signature, a PI3K Pathway Gene Signature and a Nasal Diagnostic Gene Signature) in the Nasal Epithelium of Current Smokers 10-14 Days Post Intervention', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'OG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO'}], 'classes': [{'title': 'bronchial signature', 'categories': [{'measurements': [{'value': '-1.37', 'spread': '2.69', 'groupId': 'OG000'}, {'value': '0.88', 'spread': '3.71', 'groupId': 'OG001'}]}]}, {'title': 'PI3K pathway gene signature', 'categories': [{'measurements': [{'value': '-0.16', 'spread': '1.63', 'groupId': 'OG000'}, {'value': '0.71', 'spread': '2.35', 'groupId': 'OG001'}]}]}, {'title': 'nasal diagnostic gene signature', 'categories': [{'measurements': [{'value': '2.78', 'spread': '6.35', 'groupId': 'OG000'}, {'value': '-1.98', 'spread': '11.58', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline to 14 days post intervention', 'description': 'Change (from baseline to 10-14 days off intervention) in three lung cancer gene signatures (an 80-gene bronchial signature, a PI3K pathway gene signature and a nasal diagnostic gene signature) derived from prior research was compared between the two study arms. A decreased signature score implicated a more favorable intervention effect. There is no minimum or maximum score.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The number of participants analyzed is different from the numbers provided in the Participant Flow Module because gene expression analysis was restricted to samples that met quality metrics.'}, {'type': 'SECONDARY', 'title': 'Change in Urinary PGE-M Levels', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '22', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'OG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO'}], 'classes': [{'categories': [{'measurements': [{'value': '-5.9', 'spread': '13.9', 'groupId': 'OG000'}, {'value': '0.71', 'spread': '9.3', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline to 12 weeks (End-of-intervention)', 'unitOfMeasure': 'ng/mg creatinine', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change in Urinary LTE (4) Levels', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '22', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'OG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO'}], 'classes': [{'categories': [{'measurements': [{'value': '-57.6', 'spread': '65.6', 'groupId': 'OG000'}, {'value': '35.2', 'spread': '92.7', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline to 12 weeks (End-of-intervention)', 'unitOfMeasure': 'pg/mg creatinine', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of Participants Experiencing Possibly/Probably/Definitely-related Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'OG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO'}], 'classes': [{'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to 2 weeks post-treatment', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants who have received at least one dose of the study agent.'}, {'type': 'SECONDARY', 'title': 'Gender Effect on Smoking-related Gene Expression Signature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'OG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO'}], 'classes': [{'title': 'Females', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '2.93', 'groupId': 'OG000'}, {'value': '-0.20', 'spread': '2.01', 'groupId': 'OG001'}]}]}, {'title': 'Males', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.27', 'spread': '2.99', 'groupId': 'OG000'}, {'value': '0.76', 'spread': '2.51', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline to 12 weeks (End-of-intervention)', 'description': 'Change in a nasal smoking-related gene expression signature score derived from prior research was analyzed by gender. Prior research showed that a higher score was observed in never smokers compared to current smokers. An increased score implicated a more favorable intervention effect. There is no minimum or maximum score.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The number of participants analyzed is different from the numbers provided in the Participant Flow Module because gene expression analysis was restricted to samples that met quality metrics.'}, {'type': 'SECONDARY', 'title': 'Changes in the Metabolomics Profile of the Arachidonic Acid Pathway', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'OG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO'}], 'timeFrame': 'Baseline to 12 weeks (End-of-intervention)', 'description': 'Two sample t tests will be performed to evaluate whether or not there are significant differences in changes in oxylipin metabolome between the treatment and placebo groups. In addition, system biology methods will also be used to analyze the oxylipin metabolome data.', 'reportingStatus': 'POSTED', 'populationDescription': 'Data were not collected.'}, {'type': 'SECONDARY', 'title': 'Number of Genes Differentially Expressed After Aspirin and Zileuton Intervention Compared to Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'OG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '83', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline to 12 weeks (End-of-intervention)', 'description': 'Number of genes differentially expressed after aspirin and zileuton intervention compared to placebo using whole-genome gene expression data', 'unitOfMeasure': 'gene', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Impact of ASA and Zileuton on Karyometric Analysis of Buccal Cells', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'OG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO'}], 'timeFrame': 'Up to week 12', 'reportingStatus': 'POSTED', 'populationDescription': 'Data were not collected.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'FG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '31'}, {'groupId': 'FG001', 'numSubjects': '32'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '21'}, {'groupId': 'FG001', 'numSubjects': '22'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '10'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'BG000'}, {'value': '32', 'groupId': 'BG001'}, {'value': '63', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Arm I (Aspirin, Zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.\n\nAspirin: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nZileuton: Given PO'}, {'id': 'BG001', 'title': 'Arm II (Double Placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPlacebo Administration: Given aspirin placebo PO\n\nPlacebo Administration: Given zileuton placebo PO'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '49.6', 'spread': '8.6', 'groupId': 'BG000'}, {'value': '53.5', 'spread': '10.7', 'groupId': 'BG001'}, {'value': '51.6', 'spread': '9.9', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '14', 'groupId': 'BG001'}, {'value': '27', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '18', 'groupId': 'BG001'}, {'value': '36', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '28', 'groupId': 'BG000'}, {'value': '28', 'groupId': 'BG001'}, {'value': '56', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '28', 'groupId': 'BG000'}, {'value': '24', 'groupId': 'BG001'}, {'value': '52', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '31', 'groupId': 'BG000'}, {'value': '32', 'groupId': 'BG001'}, {'value': '63', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-02-19', 'size': 619659, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2019-05-03T08:26', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 63}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-01-13', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-06', 'completionDateStruct': {'date': '2021-03-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-06-01', 'studyFirstSubmitDate': '2015-01-27', 'resultsFirstSubmitDate': '2020-03-03', 'studyFirstSubmitQcDate': '2015-01-27', 'lastUpdatePostDateStruct': {'date': '2022-06-02', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2020-03-03', 'studyFirstPostDateStruct': {'date': '2015-01-28', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2020-03-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-02-22', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers', 'timeFrame': 'Baseline to 12 weeks (End-of-intervention)', 'description': 'Change in a nasal smoking-related gene expression signature score derived from prior research was compared between the two study arms. Prior research showed that a higher score was observed in never smokers compared to current smokers. An increased score implicated a more favorable intervention effect. There is no minimum or maximum score.'}], 'secondaryOutcomes': [{'measure': 'Changes in Three Lung Cancer Gene Signatures (an 80-gene Bronchial Signature, a PI3K Pathway Gene Signature and a Nasal Diagnostic Gene Signature) in the Nasal Epithelium of Current Smokers', 'timeFrame': 'Baseline to 12 weeks (End of Intervention)', 'description': 'Change in three lung cancer gene signatures (an 80-gene bronchial signature, a PI3K pathway gene signature and a nasal diagnostic gene signature) derived from prior research was compared between the two study arms. A decreased signature score implicated a more favorable intervention effect. There is no minimum or maximum score.'}, {'measure': 'Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers 10-14 Days Post Intervention', 'timeFrame': 'Baseline to 14 days post intervention', 'description': 'Change (from baseline to 10-14 days off intervention) in a nasal smoking-related gene expression signature score derived from prior research was compared between the two study arms. Prior research showed that a higher score was observed in never smokers compared to current smokers. An increased score implicated a more favorable intervention effect. There is no minimum or maximum score.'}, {'measure': 'Changes in Three Lung Cancer Gene Signatures (an 80-gene Bronchial Signature, a PI3K Pathway Gene Signature and a Nasal Diagnostic Gene Signature) in the Nasal Epithelium of Current Smokers 10-14 Days Post Intervention', 'timeFrame': 'Baseline to 14 days post intervention', 'description': 'Change (from baseline to 10-14 days off intervention) in three lung cancer gene signatures (an 80-gene bronchial signature, a PI3K pathway gene signature and a nasal diagnostic gene signature) derived from prior research was compared between the two study arms. A decreased signature score implicated a more favorable intervention effect. There is no minimum or maximum score.'}, {'measure': 'Change in Urinary PGE-M Levels', 'timeFrame': 'Baseline to 12 weeks (End-of-intervention)'}, {'measure': 'Change in Urinary LTE (4) Levels', 'timeFrame': 'Baseline to 12 weeks (End-of-intervention)'}, {'measure': 'Number of Participants Experiencing Possibly/Probably/Definitely-related Adverse Events', 'timeFrame': 'Up to 2 weeks post-treatment'}, {'measure': 'Gender Effect on Smoking-related Gene Expression Signature', 'timeFrame': 'Baseline to 12 weeks (End-of-intervention)', 'description': 'Change in a nasal smoking-related gene expression signature score derived from prior research was analyzed by gender. Prior research showed that a higher score was observed in never smokers compared to current smokers. An increased score implicated a more favorable intervention effect. There is no minimum or maximum score.'}, {'measure': 'Changes in the Metabolomics Profile of the Arachidonic Acid Pathway', 'timeFrame': 'Baseline to 12 weeks (End-of-intervention)', 'description': 'Two sample t tests will be performed to evaluate whether or not there are significant differences in changes in oxylipin metabolome between the treatment and placebo groups. In addition, system biology methods will also be used to analyze the oxylipin metabolome data.'}, {'measure': 'Number of Genes Differentially Expressed After Aspirin and Zileuton Intervention Compared to Placebo', 'timeFrame': 'Baseline to 12 weeks (End-of-intervention)', 'description': 'Number of genes differentially expressed after aspirin and zileuton intervention compared to placebo using whole-genome gene expression data'}, {'measure': 'Impact of ASA and Zileuton on Karyometric Analysis of Buccal Cells', 'timeFrame': 'Up to week 12'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'conditions': ['Tobacco Use Disorder']}, 'descriptionModule': {'briefSummary': 'This randomized phase II trial studies the effects of aspirin and zileuton on genes related to tobacco use in current smokers. Aspirin and zileuton may interfere with genes related to tobacco use and may be useful in preventing lung cancer in current smokers.', 'detailedDescription': 'PRIMARY OBJECTIVES:\n\nI. To analyze the impact of combined treatment of acetylsalicylic acid (ASA) (aspirin) and zileuton on smoking-related gene expression signature in the nasal epithelium in current smokers and to analyze any difference between the ASA and zileuton intervention and placebo control.\n\nSECONDARY OBJECTIVES:\n\nI. To assess the impact of ASA and zileuton on three lung cancer gene signatures (an 80-gene bronchial signature, a phosphatidylinositol 3-kinase \\[PI3K\\] pathway gene signature and a nasal diagnostic gene signature) and to compare this to placebo control.\n\nII. To determine whether the change in the smoking-related gene expression signature and the three lung cancer gene signatures of nasal epithelium persists 10-14 days off agent intervention.\n\nIII. To measure urinary prostaglandin E metabolite (PGE-M) and leukotriene E(4) (LTE\\[4\\]) levels in current smokers after ASA and zileuton.\n\nIV. To assess the safety in current smokers of 12 week exposure to ASA and zileuton.\n\nV. To evaluate a gender effect in the modulatory effects of ASA and zileuton on smoking related-gene expression signature.\n\nVI. To explore the effect of ASA and zileuton on the metabolomics profile of the arachidonic acid pathway.\n\nVII. To explore, in a discovery-driven fashion, the effect of ASA and zileuton on whole-genome gene expression.\n\nVIII. To analyze the impact of ASA and zileuton on karyometric analysis of buccal cells.\n\nOUTLINE: Patients are randomized to 1 of 2 arms.\n\nARM I: Patients receive aspirin orally (PO) once daily (QD) and zileuton PO twice daily (BID) for 12 weeks in the absence of unacceptable toxicity.\n\nARM II: Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.\n\nAfter completion of study treatment, patients are followed up for 2 weeks.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Current tobacco smokers with \\>= 20 pack years of self-reported smoking exposure and an average use of \\>= 10 cigarettes/day\n* Karnofsky \\>= 70%\n* Leukocytes \\>= 3,000/microliter\n* Absolute neutrophil count \\>= 1,500/microliter\n* Hematocrit \\>= the lower institutional limit\n* Platelets \\>= the lower institutional limits\n* Total bilirubin within normal institutional limits\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) within normal institutional limits\n* Creatinine =\\< the upper institutional limits\n* Prothrombin time (PT)/partial thromboplastin time (PTT) within normal institutional limits\n* Fertile subjects must use adequate contraception (abstinence, barrier methods, or birth control pills) prior to study entry and for the duration of study participation; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately\n* Participants may have a history of indeterminate pulmonary nodule(s) by chest imaging if nodule follow-up has been completed or the study procedures would not interfere with nodule follow-up\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* History of allergic reaction to aspirin or attributed to compounds of similar chemical or biologic composition to aspirin, including other nonsteroidal anti-inflammatory drugs (NSAIDs)\n* Gastric intolerance attributable to ASA or NSAIDs\n* History of gastric ulcer within the past 5 years (with or without bleeding)\n* Use of ASA or NSAIDs for more than 5 days per month within 3 months of enrollment\n* Not willing or are unable to refrain from use of any non-study ASA, NSAIDs and leukotriene antagonists during the study period\n* Adult asthma\n* Chronic, current or recent (within the past three months) use of leukotriene antagonists\n* Require chronic anticoagulation or anti-platelet therapy\n* History of bleeding disorder or hemorrhagic stroke\n* Chronic, current or recent (within the past three months) use of glucocorticoids (systemic, topical and/or nasal sprays or steroid topical creams to large body surface area); use of steroid topical creams for small body areas (=\\< 10% body surface) during study intervention is allowed\n* History of chronic sinusitis or recent nasal polyps\n* History of, or current, active or chronic liver disease even if transaminases have normalized\n* History of allergic reaction to zileuton or attributed to compounds of similar chemical or biologic composition to zileuton\n* Are taking drugs known to interact with zileuton, including theophylline, warfarin, and propranolol\n* Not willing or are unable to limit alcohol consumption to =\\< 2 alcoholic beverages a day during the study period\n* Pregnant or lactating women; breastfeeding should be discontinued if the mother is treated with aspirin; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately\n* Participants may not be receiving any other investigational agents\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Have a known history of inability to absorb an oral agent\n* Invasive cancer within the past five years except non-melanoma skin cancer\n* Urine cotinine level, if collected at screening, does not confirm active smoking status'}, 'identificationModule': {'nctId': 'NCT02348203', 'briefTitle': 'Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers', 'organization': {'class': 'NIH', 'fullName': 'National Cancer Institute (NCI)'}, 'officialTitle': 'Clinical Study of the Effect of Combined Treatment of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers', 'orgStudyIdInfo': {'id': 'NCI-2015-00061'}, 'secondaryIdInfos': [{'id': 'NCI-2015-00061', 'type': 'REGISTRY', 'domain': 'CTRP (Clinical Trial Reporting Program)'}, {'id': 'N01-CN-2012-00031'}, {'id': '1403269898', 'type': 'OTHER', 'domain': 'Banner University Medical Center - Tucson'}, {'id': 'UAZ2013-02-01', 'type': 'OTHER', 'domain': 'DCP'}, {'id': 'N01CN00031', 'link': 'https://reporter.nih.gov/quickSearch/N01CN00031', 'type': 'NIH'}, {'id': 'P30CA023074', 'link': 'https://reporter.nih.gov/quickSearch/P30CA023074', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Arm I (aspirin, zileuton)', 'description': 'Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.', 'interventionNames': ['Drug: Aspirin', 'Other: Laboratory Biomarker Analysis', 'Drug: Zileuton']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Arm II (double placebo)', 'description': 'Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.', 'interventionNames': ['Other: Laboratory Biomarker Analysis', 'Other: Placebo Administration']}], 'interventions': [{'name': 'Aspirin', 'type': 'DRUG', 'otherNames': ['Acetylsalicylic Acid', 'ASA', 'Aspergum', 'Ecotrin', 'Empirin', 'Entericin', 'Extren', 'Measurin'], 'description': 'Given PO', 'armGroupLabels': ['Arm I (aspirin, zileuton)']}, {'name': 'Laboratory Biomarker Analysis', 'type': 'OTHER', 'description': 'Correlative studies', 'armGroupLabels': ['Arm I (aspirin, zileuton)', 'Arm II (double placebo)']}, {'name': 'Placebo Administration', 'type': 'OTHER', 'description': 'Given aspirin placebo PO', 'armGroupLabels': ['Arm II (double placebo)']}, {'name': 'Placebo Administration', 'type': 'OTHER', 'description': 'Given zileuton placebo PO', 'armGroupLabels': ['Arm II (double placebo)']}, {'name': 'Zileuton', 'type': 'DRUG', 'otherNames': ['Zyflo'], 'description': 'Given PO', 'armGroupLabels': ['Arm I (aspirin, zileuton)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85719', 'city': 'Tucson', 'state': 'Arizona', 'country': 'United States', 'facility': 'Banner University Medical Center - Tucson', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '02118', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Boston University School of Medicine', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}], 'overallOfficials': [{'name': 'Linda L Garland', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'The University of Arizona Medical Center-University Campus'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}, 'responsibleParty': {'type': 'SPONSOR'}}}}